text: SECTION 1. SHORT TITLE.
  
      This Act may be cited as the ``Heroin and Prescription Opioid Abuse 
  Prevention, Education, and Enforcement Act of 2014''.
  
  SEC. 2. FINDINGS.
  
              (1) The Controlled Substances Act (21 U.S.C. 801 et seq.) 
          declares that many controlled substances have a useful and 
          legitimate medical purpose and are necessary to maintain the 
          health and general welfare of the people of the United States.
              (2) Health care professionals, medical experts, 
          researchers, and scientists have found pain to be a major 
          national health problem.
              (3) The responsible treatment of pain is a high priority 
          for our Nation and the needs of individuals with pain must be 
          taken into careful consideration when taking steps to prevent 
          prescription drug misuse and abuse.
              (4) When no longer needed or wanted for legitimate pain 
          management or health treatment, prescription opioids are 
          susceptible to diversion. Prescription opioids also may be 
          abused by individuals who were not prescribed such drugs or 
          misused by individuals not taking such drugs as directed.
              (5) Approximately 4 out of 5 new heroin users report that 
          they became addicted to prescription opioids before they used 
          heroin for the first time.
              (6) According to the National Institute on Drug Abuse, 
          heroin attaches to the same brain cell receptors as 
          prescription opioids.
              (7) The low cost and high purity of currently available 
          heroin has contributed to an increase in heroin use.
              (8) More people are using heroin, and are using heroin at a 
          younger age. The National Survey on Drug Use and Health reports 
          that new heroin users numbered 142,000 in 2010, and increased 
          to 178,000 in 2011. In 2011, the average age at first use among 
          heroin abusers between 12 and 49 years was 22.1 years. In 2009, 
          the average age at first use among heroin abusers between 12 
          and 49 years was 25.5 years.
              (9) According to the Department of Health and Human 
          Services, heroin use rose 79 percent nationwide between 2007 
          and 2012.
              (10) Deaths from heroin overdose have significantly 
          increased in communities across the United States. According to 
          the Centers for Disease Control and Prevention, the number of 
          deaths involving heroin increased by 110 percent from 2006 to 
          2011. From 2010 to 2011, the number of heroin deaths rose from 
          3,036 to 4,397.
              (11) The Edward Byrne Memorial Justice Assistance Grant 
          Program is critical to fighting the prescription opioid abuse 
          and heroin use epidemics, and should be reauthorized and fully 
          funded.
  
  SEC. 3. DEVELOPMENT OF BEST PRESCRIBING PRACTICES.
  
      (a) Inter-Agency Task Force.--Not later than 120 days after the 
  date of enactment of this Act, the Secretary of Health and Human 
  Services (referred to in this section as the ``Secretary''), in 
  cooperation with the Secretary of Veterans Affairs, the Secretary of 
  Defense, and the Administrator of the Drug Enforcement Administration, 
  shall convene a Pain Management Best Practices Inter-Agency Task Force 
  (referred to in this section as the ``task force'').
      (b) Membership.--The task force shall be comprised of--
              (1) representatives of--
                      (A) the Department of Health and Human Services;
                      (B) the Department of Veterans Affairs;
                      (C) the Department of Defense;
                      (D) the Drug Enforcement Administration; and
                      (E) the Institute of Medicine;
              (2) the Director of the National Institutes of Health;
              (3) physicians and non-physician prescribers;
              (4) pharmacists;
              (5) experts in the fields of pain research and addiction 
          research;
              (6) representatives of--
                      (A) pain management professional organizations;
                      (B) the mental health treatment community; and
                      (C) pain advocacy groups; and
              (7) other stakeholders, as the Secretary determines 
          appropriate.
      (c) Duties.--The task force shall--
              (1) not later than 180 days after the date on which the 
          task force is convened, develop best practices for pain 
          management and prescription pain medication prescribing 
          practices, taking into consideration--
                      (A) existing pain management research;
                      (B) recommendations from relevant conferences; and
                      (C) ongoing efforts at the State and local levels 
                  and by medical professional organizations to develop 
                  improved pain management strategies;
              (2) solicit and take into consideration public comment on 
          the practices developed under paragraph (1), amending such best 
          practices if appropriate; and
              (3) develop a strategy for disseminating information about 
          the best practices developed under paragraphs (1) and (2) to 
          prescribers, pharmacists, State medical boards, and other 
          parties, as the Secretary determines appropriate.
      (d) Limitation.--The task force shall not have rulemaking 
  authority.
      (e) Report.--Not later than 270 days after the date on which the 
  task force is convened under subsection (a), the task force shall 
  submit to Congress a report that includes--
              (1) the strategy for disseminating best practices developed 
          under subsection (c);
              (2) the results of a feasibility study on linking best 
          practices developed under paragraphs (1) and (2) of subsection 
          (c) to receiving and renewing registrations under section 
          303(f) of the Controlled Substances Act (21 U.S.C. 823(f)); and
              (3) recommendations on how to apply such best practices to 
          improve prescribing practices at medical facilities of the 
          Veterans Health Administration.
  
  SEC. 4. HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM.
  
      (a) Authorization of Appropriations.--To carry out the Harold 
  Rogers Prescription Drug Monitoring Program established under the 
  Departments of Commerce, Justice, and State, the Judiciary, and Related 
  Agencies Appropriations Act, 2002 (Public Law 107-77; 115 Stat. 748), 
  there is authorized to be appropriated $9,000,000 for each of fiscal 
  years 2015 through 2019.
      (b) GAO Report.--Not later than October 1, 2016, the Comptroller 
  General of the United States shall submit to Congress a report on the 
  effectiveness of the Harold Rogers Prescription Drug Monitoring Program 
  in reducing prescription drug abuse, and, to the extent practicable, 
  any corresponding increase or decrease in the use of heroin.
  
  SEC. 5. REAUTHORIZATION OF BYRNE JUSTICE ASSISTANCE GRANT PROGRAM.
  
      Section 508 of title I of the Omnibus Crime Control and Safe 
  Streets Act of 1968 (42 U.S.C. 3758) is amended by striking ``2006 
  through 2012'' and inserting ``2015 through 2019''.
  
  SEC. 6. OFFICE OF NATIONAL DRUG CONTROL POLICY.
  
      (a) Update of Plan To Account for Increased Heroin Use.--Not later 
  than 180 days after the date of enactment of this Act, the Director of 
  the Office of National Drug Control Policy shall revise the 2011 
  Prescription Drug Abuse Prevention Plan to reassess the approach under 
  such plan to addressing prescription drug abuse in light of an increase 
  in heroin use, and to outline actions or programs that can be carried 
  out to reduce and prevent such abuse.
      (b) GAO Recommendations for Inter-Agency Coordination.--The 
  Director shall ensure that the Office of National Drug Control Policy 
  takes into account the report of the Government Accountability Office 
  entitled ``Office of National Drug Control Policy: Office Could Better 
  Identify Opportunities to Increase Program Coordination'' issued on 
  March 26, 2013 (GAO-13-333), and identifies opportunities to enhance 
  interagency coordination as part of the Prescription Drug Abuse 
  Prevention Plan, as revised under subsection (a).
  
  SEC. 7. AWARENESS CAMPAIGNS.
  
      (a) In General.--The Secretary of Health and Human Services shall 
  advance the education and awareness of providers, patients, and other 
  appropriate stakeholders regarding the risk of abuse of prescription 
  opioid drugs if such products are not taken as prescribed.
      (b) Drug-Free Media Campaign.--
              (1) In general.--The Office of National Drug Control 
          Policy, in coordination with the Secretary of Health and Human 
          Services and the Attorney General, shall establish a national 
          drug awareness campaign.
              (2) Requirements.--The national drug awareness campaign 
          under paragraph (1) shall--
                      (A) take into account the association between 
                  prescription opioid abuse and heroin use; and
                      (B) emphasize the similarities between heroin and 
                  prescription opioids and the effects of heroin and 
                  prescription opioids on the human body.
              (3) Available funds.--Funds for the national drug awareness 
          campaign may be derived from amounts appropriated to the Office 
          of National Drug Control Policy and otherwise available for 
          obligation and expenditure.
target: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2014 - Directs the Secretary of Health and Human Services (HHS) to convene a Pain Management Best Practices Inter-Agency Task Force.  Reauthorizes the Harold Rogers Prescription Drug Monitoring Program through FY2019. Requires the Comptroller General (GAO) to report on the effectiveness of the program in reducing prescription drug abuse and any corresponding increase or decrease in the use of heroin. Amends the Omnibus Crime Control and Safe Streets Act of 1968 to reauthorize the Edward Byrne Memorial Justice Assistance Grant Program through FY2019. Requires the Director of the Office of National Drug Control Policy (ONDCP) to:  revise the 2011 Prescription Drug Abuse Prevention Plan to reassess the approach to addressing prescription drug abuse in light of an increase in heroin use and to outline actions or programs to reduce and prevent such abuse, and ensure that ONDCP takes into account a specified GAO report concerning program coordination and identifies opportunities to enhance interagency coordination as part of the Plan.   Requires the Secretary to advance the education and awareness of providers, patients, and stakeholders regarding the risk of abuse of prescription opioid drugs if such products are not taken as prescribed. Directs ONDCP to establish a national drug awareness campaign that:  takes into account the association between prescription opioid abuse and heroin use, and emphasizes the similarities between heroin and prescription opioids and the effects of these on the human body.  
feat_title: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2014